Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 1.6 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aster DM Healthcare reported its Q1 FY26 results with consolidated revenue from operations rising about 7.6% year-on-year to INR 1,077.87 crores (from INR 1,001.87 crores). Profit after tax from continuing operations grew roughly 15.5% to INR 93.56 crores (from INR 81.00 crores), with EPS from continuing operations at INR 1.67 versus INR 1.49 a year ago. Standalone revenue rose about 8.4% to INR 613.04 crores, but standalone PAT comparison is skewed by last year's one-time gain of around INR 5,148 crores from the GCC business separation. The statutory auditor Deloitte Haskins & Sells issued an unmodified (clean) opinion. Other updates include a final dividend of INR 1 per share (record date August 28, 2025), completion of the preferential allotment of 1.86 crore shares to BCP Asia and Centella Mauritius, and Board approval to buy Block-D assets of Aster Whitefield Hospital from wholly owned subsidiary AMHPL for up to INR 80 crores.
Steady revenue and profit growth from core (continuing) hospital operations, backed by a clean audit, is a positive signal for shareholders. Investors should note the INR 4.39 crore exceptional charge for merger and acquisition advisory fees and the INR 80 crore related-party asset purchase from AMHPL, both of which are flagged for transparency.